HIV/hepatitis B virus co-infection: Current challenges and new strategies

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 10-17

  Lacombe, K ^a,b,c   Bottero, J ^c   Lemoine, M ^c,d   Boyd, A ^a,b   Girard, P M ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

Chronic viral hepatitis; Epidemiology; Immunodeficiency; Prevention; Qualitative systematic review

Indexed keywords

ABACAVIR; ADEFOVIR; AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CLEVUDINE; DIDANOSINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B VACCINE; IMMUNOGLOBULIN; INTERFERON; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SORAFENIB; STAVUDINE; TELBIVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; CLINICAL TRIAL; DELTA AGENT HEPATITIS; DIAGNOSTIC TEST; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENCY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDEMIC DISEASE; EPIDEMIC; GENOTYPE; HEALTH CARE ACCESS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; INFECTION CONTROL; INNATE IMMUNITY; INSULIN RESISTANCE; LABORATORY TEST; LIPODYSTROPHY; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; METABOLISM; MIXED INFECTION; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PREVALENCE; REVIEW; SIDE EFFECT; STELLATE CELL; VIRUS GENE; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 77950351715     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp414     Document Type: Review

References (106)

1. Alter M. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6-9.
2. Report UG. http://data.unaids.org/pub/Report/2009/jc1736_2008_annual_report_en.pdf (12 October 2009, date last accessed)
3. Adewole OO, Anteyi E, Ajuwon Z et al. Hepatitis B and C virus co-infection in Nigerian patients with HIV infection. J Infect Developing Countries 2009; 3: 369-75.
4. Hoffmann C, Thio C. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7: 402-9.
5. Palella FJ Jr, Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
6. Mocroft A, Brettle R, Kirk O et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663-71.
7. Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601.
8. Lewden C, May T, Rosenthal E et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005 surveys" (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48: 590-8.
9. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009; 48: 1763-71.
10. Hyung Joon Y, Lok ASF. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-81.
11. Chen C-J, Yang H-I, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
12. Iloeje U, Yang H, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
13. Thio CL, Seaberg EC, Skolasky J et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-6.
14. Salmon-Ceron D, Rosenthal E, Lewden C et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalité 2005 study. J Hepatol 2009; 50: 736-45.
15. Lacombe K, Massari V, Girard P et al. Major role of hepatitis B genotypes in liver fibrosis in HIV-HBV co-infection. AIDS 2005; 20: 419-27.
16. Lacombe K, Boyd A, Desvarieux M et al. Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus. AIDS 2007; 21: 2546-9.
17. Sheng WH, Hung CC, Kao JH et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis 2007; 44: 988-95.
18. Boyd A, Lacombe K, Miailhes P et al. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 2009; doi: 10.1111/j.1365-2893.2009.01153.x.
19. Housset C, Lamas E, Brechot C. Detection of HIV1 RNA and p24 antigen in HIV1-infected human liver. Res Virol 1990; 141: 153-9.
20. Feng H, Ana T, Ting Fang L et al. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1a-mediated stellate cell activation. Hepatology 2009; 49: 2055-67.
21. Babu CK, Suwansrinon K, Bren GD et al. HIV induces TRAIL sensitivity in hepatocytes. PLoS ONE 2009; 4: pe4623.
22. Tuyama A, Hong F, Mosoian A et al. HIV entry and replication in stellate cells promotes cellular activation and fibrogenesis: implications for hepatic fibrosis in HIV/HCV co-infection. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 57. http://www.retroconference.org/2008/Abstracts/32362.htm (12 October 2009, date last accessed).
23. Piroth L, Sene D, Pol S et al. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 2007; 21: 1323-31.
24. Thibault S, Fromentin R, Tardif M et al. TLR2 and TLR4 triggering exerts contrasting effects with regard to HIV-1 infection of human dendritic cells and subsequent virus transfer to CD4+ T cells. Retrovirology 2009; 6: 42.
25. Jun W, Zhongji M, Min J et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009; 49: 1132-40.
26. Morsica G, Tasca S, Biswas P et al. Natural killer-cell cytotoxicity in HIV-positive and HIV-negative patients with and without severe course of hepatitis B virus infection. Scand J Immunol 2005; 62: 318-24.
27. Op den Brouw ML, Binda RS, van Roosmalen MH et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009; 126: 280-9.
28. Chang JJ, Sirivichayakul S, Avihingsanon A et al. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol 2009; 83: 7649-58.
29. Thimme R, Wieland S, Steiger C et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.
30. Chauvel O, Lacombe K, Bonnard P et al. Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy. Antivir Ther 2007; 12: 1115-26.
31. Crane M, Oliver B, Matthews G et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis 2009; 199: 974-81.
32. Roe B, Coughlan S, Hassan J et al. Elevated serum levels of interferon-g-inducible protein-10 in patients coinfected with hepatitis C virus and HIV. J Infect Dis 2007; 196: 1053-7.
33. Bellini C, Keiser O, Chave J et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med 2009; 10:12-8.
34. Bonacini M, Kurz A, Locarnini S et al. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002; 122: 244-5.
35. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008; 197: S279-93.
36. Vogel M, Rockstroh JK. Hepatotoxicity and liver disease in the context of HIV therapy. Curr Opin HIV AIDS 2007; 2: 306-13.
37. Sutinen J, Hakkinen AM, Westerbacka J et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002; 16: 2183-93.
38. Lemoine M, Barbu V, Girard PM et al. Altered hepatic expression of SREBP-1 and PPARg is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006; 20: 387-95.
39. Ingiliz P, Valantin MA, Duvivier C et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49: 436-42.
40. Shrivastav S, Kino T, Cunningham T et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor fgg and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol 2008; 22: 234-47.
41. Mallet VO, Varthaman A, Lasne D et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009; 23: 1511-8.
42. Rockstroh JK, Bhagani S, Benhamou Y et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-8.
43. Piroth L, Binquet C, Vergne M et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 2002; 36: 681-6.
44. Perez-Rodriguez MT, Sopena B, Crespo M et al. Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients. World J Gastroenterol 2009; 15: 1237-41.
45. Neau D, Winnock M, Jouvencel AC et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 2005; 40: 750-3.
46. Keeffe EB. Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination. Am J Med 2005; 118:21-7.
47. Don CR, Stephen HC, Zachary DG et al. Liver biopsy. Hepatology 2009; 49: 1017-44.
48. Bottero J, Lacombe K, Guechot J et al. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. J Hepatol 2009; 50: 1074-83.
49. Ziol M, Handra-Luca A, Kettaneh A et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
50. Marcellin P, Ziol M, Bedossa P et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29: 242-7.
51. de Ledinghen V, Douvin C, Kettaneh A et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175-9.
52. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
53. Maruyama H, Yoshikawa M, Yokosuka O. Current role of ultrasound for the management of hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1710-9.
54. Chang P-E, Miquel R, Blanco J-L et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol 2009; 104: 1707-14.
55. Mallet V, Blanchard P, Verkarre V et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21: 187-92.
56. Zech CJ, Reiser MF, Herrmann KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis 2009; 27: 114-24.
57. Brook MG, McDonald JA, Karayiannis P et al. Randomised controlled trial of interferon a 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989; 30: 1116-22.
58. Di Martino V, Thevenot T, Colin JF et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123: 1812-22.
59. Marcellin P, Lau GK, Bonino F et al. Peginterferon a-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
60. Gozlan J, Lacombe K, Gault E et al. Complete cure of HBV-HDV co-infection after 24 weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV. J Hepatol 2009; 50: 432-4.
61. Ingiliz P, Valantin MA, Thibault V et al. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-a2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir Ther 2008; 13: 895-900.
62. Johnson RM, Ristig MB, Overton ET et al. Safety and tolerability of sequential pegylated IFN-α2a and tenofovir for hepatitis B infection in HIV(+) individuals. HIV Clin Trials 2007; 8: 173-81.
63. Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-6.
64. Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-23.
65. Peters MG, Andersen J, Lynch P et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44: 1110-6.
66. Lacombe K, Gozlan J, Boelle PY et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 2005; 19: 907-15.
67. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
68. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
69. Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
70. McMahon MA, Jilek BL, Brennan TP et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356: 2614-21.
71. Low E, Cox A, Atkins M et al. Telbivudine has activity against HIV-1. AIDS 2009; 23: 546-7.
72. Yoo BC, Kim JH, Kim TH et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007; 46: 1041-8.
73. Yoo BC, Kim JH, Chung YH et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45: 1172-8.
74. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009; 51: 787-91.
75. Soriano V, Puoti M, Peters M et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22: 1399-410.
76. Vogel M, Rockstroh JK. Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS 2009; 4: 171-5.
77. Pessoa MG, Gazzard B, Huang AK et al. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008; 22: 1779-87.
78. Benhamou Y, Thibault V, Vig P et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44:62-7.
79. Matthews GV, Avihingsanon A, Lewin SR et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48: 1062-9.
80. Matthews GV, Seaberg E, Dore GJ et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS 2009; 23: 1707-15.
81. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-50.
82. Jardi R, Rodriguez-Frias F, Schaper M et al. Analysis of hepatitis B genotype changes in chronic hepatitis B infection: influence of antiviral therapy. J Hepatol 2008; 49: 695-701.
83. Chan HL, Tse CH, Mo F et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26: 177-82.
84. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
85. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25: 97-106.
86. Kamili S, Sozzi V, Thompson G et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009; 49: 1483-91.
87. Sheldon J, Ramos B, Garcia-Samaniego J et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 2007; 46: 279-82.
88. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47: 451-60.
89. Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
90. Maynard M, Parvaz P, Durantel S et al. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J Hepatol 2005; 42: 279-81.
91. Zoulim F, Mimms L, Floreani M et al. New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection. J Clin Microbiol 1992; 30: 1111-9.
92. Brunetto MR, Moriconi F, Bonino F et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon a-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
93. Sulkowski M. Hepatocellular carcinoma in HIV-infected patients comes of age: the convergence of epidemiology and treatment effectiveness. J Hepatol 2009; 50: 655-8.
94. Subramanian A, Sulkowski M, Barin B et al. MELD is the best predictor of pre-transplant mortality in HIV-infected liver transplant candidates. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 64.http://www.retroconference.org/2008/Abstracts/31927.htm (12 October 2009, date last accessed).
95. Tateo M, Roque-Afonso A-M, Antonini TM et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009; 23: 1069-76.
96. Verslype C, Van Cutsem E, Dicato M et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 2009; 20: vii1-6.
97. El-Serag HB, Marrero JA, Rudolph L et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-63.
98. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
99. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol 2009; 21: 445-54.
100. WHO. Essential Prevention and Care Interventions for Adults and Adolescents Living with HIV in Resource-limited Settings. http://www.who.int/hiv/pub/plhiv/plhiv_treatment_care.pdf (12 October 2009, date last accessed).
101. WHO. HIV/AIDS Prevention, Treatment and Care in the Health Sector. http://www.who.int/entity/hiv/pub/priority_interventions_web.pdf (12 October 2009, date last accessed).
102. Lessells RJ, Main J, Cooke GS. HIV and hepatitis B co-infection in Africa. Lancet Infect Dis 2008; 8: 210-1.
103. Wiseman E, Fraser MA, Holden S et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190: 489-92.
104. Liu S-L, Dong Y, Zhang L et al. Influence of HBV gene heterogeneity on the failure of immunization with HBV vaccines in eastern China. Arch Virol 2009; 154: 437-43.
105. Xu WM, Cui YT, Wang L et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94-103.
106. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-44.